Luminal and basal subtypes as biomarkers in prostate cancer
Abstract
Scientific Objective and Rationale: There are many options for the treatment of men with prostate cancer. However, no treatment is perfect, and there will always be men who benefit a great deal and should be recommended a particular treatment, and there will be men who do not benefit at all and may even be harmed by the treatment, who should be recommended a different treatment. The objective of this study is to develop a test to understand each patient’s tumor in order to decide whether a particular treatment is likely to help them. Ultimate Applicability of this Research: This research will be highly applicable to patients with prostate cancer because the testing platform is already commercially available. We are proposing to develop a new algorithm on this platform. This means that our findings can be easily moved into clinical practice. Contributions of This Study to the FY19 PCRP Overarching Challenges: This study will address two of the FY19 PCRP Overarching Challenges. It will improve the quality of life for survivors of prostate cancer because predicting which patients will benefit from a specific treatment also lets us identify which patients will not benefit and which can be spared potential side effects from a treatment that would not help them. This in turn will improve their quality of life. This study will also define the biology of lethal prostate cancer to reduce death. It will better characterize the subtypes and associated DNA changes to better understand the biology of metastatic prostate cancer, the lethal form of the disease. It will also establish whether the subtypes can predict who may benefit from a specific type of chemotherapy that will also help reduce death from prostate cancer. Types of Patients This Work Will Help and How It Will Help Them: This study provides benefit to men with a recurrence after surgery for primary prostate cancer in deciding whether hormonal therapy is right for them based on their individual tumor. This study also provides important information for men with metastatic prostate cancer in determining whether they would benefit from a specific type of chemotherapy. Potential Clinical Applications, Benefits, and Risks: If this proposal is completed successfully, it can be applied directly to the patient population defined above to help select treatment. The potential benefit is to deliver the best treatment to the patient that will benefit the most and avoid over-treating patients who would not benefit and could be harmed by treatment. The risks are low because patients who have surgery for primary prostate cancer already have their tumor taken out, so they do not undergo any additional procedures or risks. Biopsies of metastatic patients are less common currently, so there is a small chance of a side effect from a biopsy procedure, though these are generally safe. Should the subtypes provide important information on what treatment to use for a particular patient, the benefit would likely outweigh the small risk from a biopsy. Projected Time It May Take to Achieve a Patient-Related Outcome: Should the proposal be successful, a test would be potentially ready for clinical use at the end of the 4-year proposal. Principal Investigator’s (PI) Career Goals in Prostate Cancer Research and Patient Care: My career goal is to be a physician-scientist who provides personalized care to men with prostate cancer in my radiation oncology clinic. I will also strive to helps develop biomarkers and understand the biology of prostate in my research laboratory. How the Research Plan Supports the PI in Achieving These Goals: This research plan will support the testing of the first biomarker for selecting hormone therapy in prostate cancer, which I developed, in a randomized control trial to support its use in patients. It will also allow me to gain additional experience in developing biomarkers, especially in randomized trials, and using next-genera
Document Details
- Document Type
- DoD Grant Award
- Publication Date
- Mar 10, 2021
- Source ID
- W81XWH2010799
Entities
People
- Shuang G. Zhao
Organizations
- United States Army
- University of Wisconsin–Madison